Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, immunogenicity, efficacy and pharmacokinetics of N8-GP in previously treated paediatric patients with severe haemophilia A
2012-001711-23Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Incidence of FVIII inhibitory antibodies. Started Nov 2012; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2012-001711-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001711-23.